Department of Pathology and Cancer Screening, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Kolkata, 700026, India.
Med Oncol. 2022 May 15;39(5):74. doi: 10.1007/s12032-022-01675-2.
Triple-negative breast cancer lacks an expression of ER, PR, and Her-2, has a poor prognosis, and there are no target therapies available. Therapeutic options to treat TNBC are limited and urgently needed. Strong evidence indicates that molecular signaling pathways have a significant function to regulate biological mechanisms and their abnormal expression endows with the development of cancer. PIM kinase is overexpressed in various human cancers including TNBC which is regulated by various signaling pathways that are crucial for cancer cell proliferation and survival and also make PIM kinase as an attractive drug target. One of the targets of the STAT3 signaling pathway is PIM1 that plays a key role in tumor progression and transformation. In this review, we accumulate the current scenario of the PIM-STAT3 axis that provides insights into the PIM1 and STAT3 inhibitors which can be developed as potential co-inhibitors as prospective anticancer agents.
三阴性乳腺癌缺乏 ER、PR 和 Her-2 的表达，预后不良，目前尚无可用的靶向治疗方法。治疗 TNBC 的治疗选择有限，因此迫切需要新的治疗方法。有强有力的证据表明，分子信号通路在调节生物学机制方面具有重要作用，其异常表达赋予了癌症的发展。PIM 激酶在包括 TNBC 在内的各种人类癌症中过度表达，其受到各种信号通路的调控，这些信号通路对癌细胞的增殖和存活至关重要，也使 PIM 激酶成为一个有吸引力的药物靶点。STAT3 信号通路的一个靶点是 PIM1，它在肿瘤的进展和转化中起着关键作用。在这篇综述中，我们总结了 PIM-STAT3 轴的最新情况，为开发 PIM1 和 STAT3 抑制剂作为有前途的抗癌药物提供了新的思路。
